LES LSS Webinar: Academic-Industry vs. Industry-Industry Therapeutic Licensing Terms

Therapeutic assets traverse many development stages and developers between discovery and the patient. At a transition between one developer and the next, those of us negotiating the licensing deal have to account for unfamiliar risks or help satisfy stakeholders with little connection to the development path. The licensing terms we use may not be optimized for incentivizing later stages or aligning with prior obligations.

In this webinar, we’ll compare at least two of these transitions: common license terms from Academia to Biotech and those from Biotech to Pharma including sublicensing and milestones. For example, what is a “commercially reasonable standard” and how is a tech transfer office supposed to judge one? How should you address the sublicensing expectations of a non-profit when that expected to be a major part of your return?

Key learnings objectives include:
-Boilerplate terms in academic licenses and the reason they exist
-Common diligence language in biotech licenses
-Sublicensing terms, valuation and misunderstandings
-Optimization of terms to avoid renegotiation

 

Members: Free

Nonmembers: $69